ADVFN Logo ADVFN

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Axsome Therapeutics Inc

Axsome Therapeutics Inc (AXSM)

131.15
-0.53
(-0.40%)
Closed February 16 4:00PM
131.09
-0.06
(-0.05%)
After Hours: 7:13PM
Advanced chart

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
131.09
Bid
132.10
Ask
132.50
Volume
1,057,383
129.35 Day's Range 132.12
64.11 52 Week Range 134.185
Market Cap
Previous Close
131.68
Open
131.61
Last Trade
3
@
132.49
Last Trade Time
19:42:08
Financial Volume
$ 138,728,438
VWAP
131.1998
Average Volume (3m)
871,522
Shares Outstanding
48,462,376
Dividend Yield
-
PE Ratio
-26.57
Earnings Per Share (EPS)
-4.94
Revenue
270.6M
Net Profit
-239.24M

About Axsome Therapeutics Inc

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
Axsome Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker AXSM. The last closing price for Axsome Therapeutics was $131.68. Over the last year, Axsome Therapeutics shares have traded in a share price range of $ 64.11 to $ 134.185.

Axsome Therapeutics currently has 48,462,376 shares outstanding. The market capitalization of Axsome Therapeutics is $6.38 billion. Axsome Therapeutics has a price to earnings ratio (PE ratio) of -26.57.

Axsome Therapeutics (AXSM) Options Flow Summary

Overall Flow

Bullish

Net Premium

145k

Calls / Puts

100.00%

Buys / Sells

50.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

AXSM Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
121.7819.9249839905109.31134.185105.511718594126.77290504CS
437.0739.427781323194.02134.18591.811131644114.03784496CS
1232.5933.086294416298.5134.18575.56871522100.3458367CS
264654.060406628385.09134.18575.5663561596.73319534CS
5237.2239.650580590293.87134.18564.1166898986.57408548CS
15699.73318.01658163331.36134.18520.6393058264.82539368CS
26041.9747.093806104189.12134.18519.3880898761.34198565CS

AXSM - Frequently Asked Questions (FAQ)

What is the current Axsome Therapeutics share price?
The current share price of Axsome Therapeutics is $ 131.09
How many Axsome Therapeutics shares are in issue?
Axsome Therapeutics has 48,462,376 shares in issue
What is the market cap of Axsome Therapeutics?
The market capitalisation of Axsome Therapeutics is USD 6.38B
What is the 1 year trading range for Axsome Therapeutics share price?
Axsome Therapeutics has traded in the range of $ 64.11 to $ 134.185 during the past year
What is the PE ratio of Axsome Therapeutics?
The price to earnings ratio of Axsome Therapeutics is -26.57
What is the cash to sales ratio of Axsome Therapeutics?
The cash to sales ratio of Axsome Therapeutics is 23.49
What is the reporting currency for Axsome Therapeutics?
Axsome Therapeutics reports financial results in USD
What is the latest annual turnover for Axsome Therapeutics?
The latest annual turnover of Axsome Therapeutics is USD 270.6M
What is the latest annual profit for Axsome Therapeutics?
The latest annual profit of Axsome Therapeutics is USD -239.24M
What is the registered address of Axsome Therapeutics?
The registered address for Axsome Therapeutics is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Axsome Therapeutics website address?
The website address for Axsome Therapeutics is www.axsome.com
Which industry sector does Axsome Therapeutics operate in?
Axsome Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CCTGCCSC Technology International Holdings Ltd
$ 2.75
(50.27%)
1.03M
GLYCGlycoMimetics Inc
$ 0.4198
(44.76%)
12.27M
EDBLEdible Garden AG Inc
$ 0.250121
(24.13%)
9.83M
HCTIHealthcare Triangle Inc
$ 0.58
(21.11%)
6.57M
AVGRAvinger Inc
$ 0.57
(20.25%)
234.98k
INLFINLIF Limited
$ 11.86
(-27.37%)
450.13k
MGOLMGO Global Inc
$ 0.53
(-26.14%)
36.46M
BHATBlue Hat Interactive Entertainment Technology
$ 0.0499
(-19.52%)
24.18M
TOIIWOncology Institute Inc
$ 0.0204
(-18.07%)
467
RVYLRYVYL Inc
$ 1.0701
(-15.07%)
50.96k
MGOLMGO Global Inc
$ 0.53
(-26.14%)
36.46M
BHATBlue Hat Interactive Entertainment Technology
$ 0.0499
(-19.52%)
24.18M
ADTXAditxt Inc
$ 0.0683
(-2.43%)
21.59M
GLYCGlycoMimetics Inc
$ 0.4198
(44.76%)
12.27M
EDBLEdible Garden AG Inc
$ 0.250121
(24.13%)
9.83M

AXSM Financials

Financials

AXSM Discussion

View Posts
georgejjl georgejjl 4 days ago
axsome therapeutics to report fourth quarter and full year 2024 financial results on February 18, 2025

10K submitted to the US SEC.

https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-report-fourth-quarter-and-full-year-2024

Good luck and GOD bless,
👍️0
georgejjl georgejjl 6 days ago
AXSM stock price should go up near the close of trading today and tomorrow!!!

Good luck and GOD bless
👍️0
georgejjl georgejjl 6 days ago
"...Teva Pharmaceuticals is a major pharmaceutical company that produces over-the-counter (OTC) drugs. Teva is the world's largest generic drug supplier and has a wide range of products, including generics, OTC drugs, and specialty treatments. ...

https://en.wikipedia.org/wiki/Teva_Pharmaceuticals#:~:text=Teva%20Pharmaceuticals%20is%20the%20largest,to%20inflate%20prices%20for%20drugs.

Good luck and GOD bless,
👍️0
gail gail 6 days ago
still going up, wow!
👍️ 1 💯 1
georgejjl georgejjl 6 days ago
Secured patent protection for AUVELITY until at least September 2038
Resolution of all outstanding patent litigation
Protected market exclusivity for 14+ years

https://www.stocktitan.net/news/AXSM/axsome-therapeutics-announces-settlement-agreement-resolving-8uzudzwdqmke.html

Good luck and GOD bless,
👍️0
georgejjl georgejjl 6 days ago
That is an ABSOLUTELY GREAT DEAL WITH TEVA!!!

https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-settlement-agreement-resolving

Good luck and GOD bless,
👍️0
chainma1l chainma1l 6 days ago
Holy shit. Yeah, great announcement, but didn't change a whole heck of a lot. I guess it really just educated a lot of people on how well-positioned AXSM is. I was expecting $120 after 07 approval. Should be at $150.
👍️ 1
Frankestin Frankestin 6 days ago
Good deal with Teva!
It would be fantastic if there were more… maybe to sell outside the US market.
👍️ 1 💯 1
Frankestin Frankestin 6 days ago
https://www.marketbeat.com/instant-alerts/strategic-financial-concepts-llc-acquires-new-position-in-axsome-therapeutics-inc-nasdaqaxsm-2025-02-10/
👍️ 1 💢 1
Frankestin Frankestin 6 days ago
"This outcome is better than our base case, which assumed exclusivity through 2037"- brokerage Truist Securities
https://www.tradingview.com/news/reuters.com,2025:newsml_L4N3P110M:0-axsome-therapeutics-rises-on-settlement-with-teva-for-depression-drug/
👍️ 1
Frankestin Frankestin 6 days ago
unexpected good news!
Very good!
https://www.stocktitan.net/news/AXSM/axsome-therapeutics-announces-settlement-agreement-resolving-8uzudzwdqmke.html
👍️0
Frankestin Frankestin 1 week ago
maybe they communicate it like this... it seems to me that there is something different compared to the November presentation... Maybe it has been presented and now we are waiting for an acceptance response?

https://www.axsome.com/axs-portfolio/pipeline/
👍️0
Paullee Paullee 2 weeks ago
They are doing ok with sunosi, but I think they may have gotten that for it salesforce help
👍️0
chainma1l chainma1l 2 weeks ago
I don't think HT is going to sell anytime soon, but I think it would take 25 billion to even get his attention right now. 2 years it'll be 50 billion. Somewhere in the middle next year. And one of the big ones is going to have to pony up strictly as a defensive maneuver. The acquirer will obviously get a massive portfolio, but I think the main impetus is to not lose market share. AXS-05 would make AXSM profitable just off the number of indications coming. 07 has the potential for blockbuster. Migraine sufferers are all going to want to try it. 8 other indications in late stage. I'm a little bothered that they spent the money to acquire Sunosi, but HT knows what he's doing. I think one of their other drugs may end up as an off-label weight loss drug.
👍️0
Frankestin Frankestin 2 weeks ago

EMERGE Ph 3 trial of AX-07 in CGRP non-responders (4Q 2024)
ENGAGE Ph 3 trial of solriamfetol in BED (2025)
PARADIGM Ph 3 trial of solriamfetol in MDD (1Q 2025)
FOCUS Ph 3 trial of solriamfetol in ADHD (1Q 2025)
AND
Chief Executive Officer Herriot Tabuteau indicated that the company plans to swiftly advance towards filing a New Drug Application (NDA) for AXS-12. The company intends to request a pre-NDA meeting with the U.S. Food and Drug Administration (FDA).
Axsome to File NDA Following Positive Phase 3 Results of AXS-12 in Narcolepsy
AXS-12 significantly reduced cataplexy attacks and improved excessive daytime sleepiness, cognition, and work productivity in narcolepsy patients.
The ENCORE trial showed a 77% reduction in cataplexy attacks at 6 months, with sustained improvements in concentration and narcolepsy symptoms.
AXS-12 was well-tolerated, with no new safety signals, and demonstrated a favorable long-term safety and tolerability profile.
Axsome Therapeutics plans to file a new drug application for AXS-12, supported by positive results from the ENCORE and SYMPHONY trials.
Over the 6-month treatment period, patients saw improvements in cataplexy frequency, excessive daytime sleepiness, cognition, and work productivity with AXS-12.
👍️0
Frankestin Frankestin 2 weeks ago
AXS-07 🤪😁😁🤩🤩🤪


👍️0
Frankestin Frankestin 2 weeks ago
🔥 FDA APPROVES SYMBRAVO! 🔥

Axsome Therapeutics ($AXSM) is changing the game in CNS treatments once again with another breakthrough approval! SYMBRAVO is now officially approved for the acute treatment of migraines, delivering a faster, more effective, and longer-lasting option than existing therapies.

💊 Single dose ? Pain relief in 2 hours, sustained up to 48 hours
📊 85% of patients did not need rescue medication
⚡ MoSEIC™ technology ? 5x faster absorption
🚀 Clinically superior to rizatriptan

With over 39 million migraine sufferers in the U.S. alone, Axsome is gearing up to capture a multibillion-dollar market. Commercial launch expected in ~4 months… time to load up before Wall Street catches on?
Relax, they’re keeping it low… After all, why would a company with a newly FDA-approved drug and a multibillion-dollar market go up, right? Maybe it’ll climb slowly… unless, of course, those who want in keep pretending they don’t like it.

https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-fda-approval-symbravor-meloxicam
👍️0
Frankestin Frankestin 2 weeks ago
Tomorrow The News
financial results for the fourth quarter and full year of 2024 on Tuesday, February 18, 2025,
I would see something else in the middle
👍️0
Frankestin Frankestin 1 month ago
Truist Securities raises PT to $180 from $150 😮
The next two weeks will be eventful
AXS-07, a candidate for the acute treatment of migraines, with expectations for regulatory approval
NDA for AXS-14 for fibromyalgia... maybe yes or maybe no
👍️0
chainma1l chainma1l 1 month ago
And I'm not going to say AXS-05 for AA is a given/slamdunk, but since the best existing option basically says on the label "people have died from taking this medication, so be aware of that" and the medication doesn't even work as well as AXS-05, there is no LOGICAL reason the FDA should not approve it for that indication.
From RickSanders9 on StockTwits:
"There appear to be 6 PDUFA's in January.
1/2: Decision already rendered.
1/7: Decision already rendered.
1/15: ATRA
1/25: BIIB
1/30: Decision already rendered.
1/31: Axsome

FDA shockingly is ahead of schedule...could be an early call on 07."

With the CRL being about manufacturing process and Axsome having gone through the same thing with ASX-05, I don't think an early decision is far fetched.
👍️0
Frankestin Frankestin 1 month ago
AXS-07, with a PDUFA action goal date of January 31st, 2025.
Launch preparations are underway to ensure timely commercialization if approved.
AXS-14 for the management of fibromyalgia, we are completing preparations for the NDA submission and expect to submit the NDA to the FDA this month.
they will have presented it around the end of November so they will have an answer near another catalist...
👍️0
Frankestin Frankestin 3 months ago
Someone said... With respect to AXS-14 for the management of fibromyalgia, we are completing preparations for the NDA submission and expect to submit the NDA to the FDA this month.
… was he wrong?
🧐
👍️0
georgejjl georgejjl 5 months ago
Wells Fargo Initiates Coverage of Axsome Therapeutics (AXSM) with Overweight Recommendation

https://fintel.io/news/wells-fargo-initiates-coverage-of-axsome-therapeutics-axsm-with-overweight-recommendation-290

Good luck and GOD bless,
👍️0
georgejjl georgejjl 5 months ago
xsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of the Company’s New Drug Application (NDA) for AXS-07 for the acute treatment of migraine. The FDA designated the resubmission as a Class 2 resubmission and set a Prescription Drug User Fee Act (PDUFA) action goal date of January 31, 2025.

https://finance.yahoo.com/news/axsome-therapeutics-announces-fda-acceptance-110000999.html

Good luck and GOD bless,
👍️0
chainma1l chainma1l 6 months ago
Cramer is the kiss of death.
👎️ 1
georgejjl georgejjl 6 months ago
AXSM stock price should be much higher after Jim Cramer said that AXSM stock price should double.

Good luck and GOD bless,
👍️0
georgejjl georgejjl 6 months ago
Jim Cramer Thinks Axsome Therapeutics Inc (NASDAQ:AXSM) Stock Can Double

https://finance.yahoo.com/news/jim-cramer-thinks-axsome-therapeutics-094318378.html

Good luck and GOD bless,
👍️0
sunspotter sunspotter 10 months ago
"I think free InvestorsHub gets you better info than $9/mo for InvestorVillage."

I think the National Enquirer gives you better info than InvestorVillage, which was always an iHub copycat but only allows favorable posts and is moderated by paid pimps.

Sadly the new iHub regime with its unfettered personal attacks and off-topic posts is not much better nowadays.
👍️0
chainma1l chainma1l 10 months ago
I tried to log in with my free account yesterday and the site said they were forced to go paid subscription only because of some hack/breach/problem. I think free InvestorsHub gets you better info than $9/mo for InvestorVillage.
👍️0
Paullee Paullee 10 months ago
Right now the IV site is closed because of a hack they haven't been able to solve. IF and when they come back it may or may not only be subscription. Too early to tell yet.
👍️0
chainma1l chainma1l 10 months ago
Anybody with an account on InvestorVillage mind posting weekly script numbers here? Too bad they went subscription only. A lot of good posters and boards over there. Maybe some will move over here.
👍️0
Frankestin Frankestin 11 months ago
Axsome Therapeutics Inc (AXSM.O): RBC $128 from $123

NDA resubmission for AXS-07!!!
Who knows how long it will take them to give the answer on this?
The CRL did not identify or raise any concerns about the clinical efficacy or safety data in the NDA, and the FDA did not request any new clinical trials to support the approval of AXS-07.
The principal reasons given in the CRL relate to chemistry, manufacturing, and controls (CMC) considerations. The CRL identified the need for additional CMC data pertaining to the drug product and manufacturing process. Axsome believes that the issues raised in the CRL are addressable and intends to provide potential timing for a resubmission following consultation with the FDA.
🥒🥒🥒🥒🥒🥒🥒
👍️0
Frankestin Frankestin 11 months ago
AXS-12 statistically significantly reduced cataplexy attacks compared to placebo (p=0.018, primary endpoint)
AXS-12 achieved statistically significant remission of cataplexy compared to placebo (p=0.008)
AXS-12 statistically significantly reduced excessive daytime sleepiness (EDS) severity compared to placebo (p=0.027, CGI-S for EDS)
AXS-12 statistically significantly improved concentration and memory compared to placebo (p=0.004, Cognitive Function items of FOSQ-10)
AXS-12 statistically significantly reduced overall severity of narcolepsy compared to placebo (p=0.007, CGI-S for narcolepsy)
AXS-12 statistically significantly improved overall function and quality of life compared to placebo (p=0.005, FOSQ-10 total score)
Company to host conference call and webcast today at 8:00 AM ET
👍️ 2
Frankestin Frankestin 11 months ago
Leerink Partners Global Biopharma Conference on Wednesday, March 13, at 9:20
Too!
👍️0
Frankestin Frankestin 11 months ago
When does it start? 1Q is about to end 🤞
Cowen 44th Annual Healthcare Conference on Wednesday, March 6, from 9:50-10:20 a.m. Eastern Time at the Marriott Copley Place in Boston, Massachusetts.
👍️0
Frankestin Frankestin 12 months ago
Axsome Therapeutics Inc (AXSM.O): Piper Sandler raises price target to $115 from $113
👍️0
Frankestin Frankestin 12 months ago
Total 4Q and full year 2023 net product revenue of $71.5 million and $204.9 million, respectively, representing year-over-year growth of 193% and 309%
Cash and cash equivalents totaled $386.2 million at December 31, 2023, compared to $200.8 million at December 31, 2022.
Net loss for the fourth quarter of 2023 was $98.7 million or $(2.08) per share
Financial Guidance * Axsome believes that its current cash is sufficient to fund anticipated operations into cash flow positivity, based on the current operating plan.

NDA submission for AXS-14 in fibromyalgia and NDA resubmission for AXS-07 in migraine, both anticipated in 1H 2024
Topline results of the SYMPHONY Phase 3 trial in narcolepsy anticipated in 1Q 2024
Topline results of the ADVANCE-2 Phase 3 trial in Alzheimer’s disease agitation and the FOCUS Phase 3 trial in ADHD expected in 2H 2024
Initiation of Phase 3 trials of solriamfetol in major depressive disorder MDD, binge eating disorder BED, and shift work disorder SWD expected 1Q 2024

* Pivotal Phase 2/3 trial of AXS-05 for smoking cessation (2024) Conference Call Information
👍️ 1
Frankestin Frankestin 1 year ago
TIC TOC TIC TOC TIC TOC TIC TOC TIC TOC TIC TOC TIC TOC TIC
June is around the corner!
Axsome Therapeutics Inc (AXSM.O): Mizuho raises target price to $112 from $90
👍️0
Monksdream Monksdream 1 year ago
AXSM new 52 week high
👍️0
Frankestin Frankestin 1 year ago
POO PO PO PO PO POOOO POO
👍️0
Monksdream Monksdream 1 year ago
AXSM new 52 week high
👍️0
Frankestin Frankestin 1 year ago
https://www.streetinsider.com/New+Coverage/UBS+Starts+Axsome+Therapeutics+%28AXSM%29+at+Buy/22723904.html
What will the shorts do?
👍️0
Frankestin Frankestin 1 year ago
Shares Outstanding 47,319,547 shares
Insider Shares 15,231,463 shares
Insider Ownership 32.19 %
Total Insiders 12
Istitutional Shares (Long) 40,227,033 - 85.01% (ex 13D/G) - change of 2.82MM shares 7.55% MRQ
Short Interest 8,319,949 shares - source: NASDAQ
Short Interest Ratio 19.14 Days to Cover
Short Interest % Float 23.89 % - source: NASDAQ (short interest), Capital IQ (float)
👍️0
Frankestin Frankestin 1 year ago


👍️0
georgejjl georgejjl 1 year ago
Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Latest Share Price Upside: 85%

Number of Q3 2023 Hedge Fund Investors: 31

Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a biotechnology firm developing treatments for nervous system diseases and disorders. Like several other stocks on our list, the shares are also rated Strong Buy on average and analysts have set an average share price target of $115.45.

Insider Monkey scoured 910 hedge fund portfolios for this year's third quarter to find 31 stakeholders in the company. Axsome Therapeutics, Inc. (NASDAQ:AXSM)'s largest hedge fund investor is Mark Lampert's Biotechnology Value Fund / BVF Inc due to its $148 million investment.

https://finance.yahoo.com/news/11-best-upside-stocks-buy-145018690.html

Good luck and GOD bless,
👍️0
georgejjl georgejjl 1 year ago
AXSM price per share catalysts on the horizon or imminent

Axsome: Leading Neuroscience Portfolio

> Axsome is committed to developing novel therapies for the millions of patients living with
serious central nervous system disorders

> Axsome’s industry-leading neuroscience portfolio ? 5 commercial or late-stage product
candidates, 8 different indications:
o 2 FDA-approved, differentiated commercial products each with blockbuster potential
(AUVELITY™ for MDD, and SUNOSI® for EDS in narcolepsy and OSA)
o 1 NDA-stage product candidate (AXS-07 for migraine)
o 2 Phase 3-stage product candidates with potential NDA filings in 2023 (AXS-12 for
narcolepsy, and AXS-14 for fibromyalgia)
o 3 follow-on indications in or ready to enter Phase 3 (Alzheimer’s disease agitation, smoking
cessation for AXS-05; ADHD for solriamfetol)

See slide #7

https://axsometherapeuticsinc.gcs-web.com/static-files/c43e73fb-f3d7-4f3d-b614-d18143abe31c

Good luck and GOD bless,
👍️0
georgejjl georgejjl 1 year ago
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced a presentation of data from its ACCORD Phase 3 clinical trial of AXS-05, a novel, oral NMDA receptor antagonist and sigma-1 receptor agonist, in patients with Alzheimer’s disease agitation (ADA), at the 16th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, being held in Boston from Oct. 24-27.

“Agitation associated with Alzheimer's dementia is a common and impactful behavioral symptom causing significant distress for patients and their care partners,” said George Grossberg, MD, study author, Professor and Director of the Division of Geriatric Psychiatry at the Saint Louis University School of Medicine. “Agitation is also a significant risk factor for early admission to long term care facilities. The outcome of the ACCORD trial with AXS-05 demonstrating positive efficacy results in agitation associated with Alzheimer's dementia, while being generally well-tolerated, is welcome news."

Results of the trial demonstrated rapid and sustained clinical response in patients with ADA during the open-label AXS-05 treatment phase. During the placebo-controlled randomized withdrawal phase, AXS-05 statistically significantly delayed the time to relapse of agitation symptoms as compared to placebo. AXS-05 was generally well-tolerated in the trial with no new safety signals identified.

“Agitation, which is seen in up to 70% of people with Alzheimer’s disease, is among the most complex, challenging and costly aspects of care and is associated with multiple negative outcomes such as increased caregiver burden, morbidity, mortality, earlier nursing home placement, and overall functional impairment,” said Cecilia Brain, MD, PhD, Vice President of Medical Affairs at Axsome. “The detailed efficacy and safety results of the ACCORD trial support the potential of AXS-05 in this area of significant unmet medical need.”

The poster will be available for viewing in the Poster Hall from 7:30 a.m. Eastern Time on Wednesday, Oct. 25 to 4:30 p.m. Eastern Time on Friday, Oct. 27. Poster presenters will be on hand for discussion from 7:30-8:30 a.m. Eastern Time as well as during the morning and afternoon coffee breaks each day during the CTAD conference. The poster will also be available through the CTAD digital platform.

https://finance.yahoo.com/news/axsome-therapeutics-presents-results-accord-110000892.html

Good luck and GOD bless,
👍️0
someconcerns someconcerns 2 years ago
Per Fidelity:

BY Benzinga
— 6:18 AM ET 07/17/2023
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Axsome Therapeutics NASDAQ:AXSM with a Buy and lowers the price target from $200 to $190.
👍️ 1
georgejjl georgejjl 2 years ago
New mid term topic $100.00 by or before the end of 2023.
👍️0
rosemountbomber rosemountbomber 2 years ago
Their target has been reached. Now what?
👍️0

Your Recent History

Delayed Upgrade Clock